HEPA - a good buy opportunity? Very likely for me!
First of all, I am not an expert when it comes to pharmaceutical companies!
Why did I pick Hepion Pharmaceuticals (@hepionpharma)?
1. From a business perspective, they are healthy (Quick Ration of Assets vs. Liabilities is 9 to 1)
2. They came from a super high share price and are currently on a super low level
3. They are working on a product CRV431 (recently completed Phase 1 of 3) to tackle chronic liver disease and so far the results seem promising: Half a billion people worldwide are at risk unless new therapies are found.
CRV431 is Hepion’s clinical phase, lead oral drug candidate for nonalcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease. CRV431 meets all of Hepion’s criteria for an effective and unique pleiotropic liver disease drug.
Currently Phase 1 consists of three parts and the collective data from the Parts 1 and 2 demonstrate a favorable pharmacological, pharmacokinetic, and safety profile for CRV431. Part 3 data results are expected and with Phase 2 we might see bigger interest.
Take a look at the chart and the health of the company with future prospective - then shape your own opinion.
- This is no financial advice, so trade with care!-
For transparency reasons: I am invested in
HEPA with 2/10 of my stock account size.
Why did I pick Hepion Pharmaceuticals (@hepionpharma)?
1. From a business perspective, they are healthy (Quick Ration of Assets vs. Liabilities is 9 to 1)
2. They came from a super high share price and are currently on a super low level
3. They are working on a product CRV431 (recently completed Phase 1 of 3) to tackle chronic liver disease and so far the results seem promising: Half a billion people worldwide are at risk unless new therapies are found.
CRV431 is Hepion’s clinical phase, lead oral drug candidate for nonalcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease. CRV431 meets all of Hepion’s criteria for an effective and unique pleiotropic liver disease drug.
Currently Phase 1 consists of three parts and the collective data from the Parts 1 and 2 demonstrate a favorable pharmacological, pharmacokinetic, and safety profile for CRV431. Part 3 data results are expected and with Phase 2 we might see bigger interest.
Take a look at the chart and the health of the company with future prospective - then shape your own opinion.
- This is no financial advice, so trade with care!-
For transparency reasons: I am invested in
HEPA with 2/10 of my stock account size.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.